Disease outcome and associated factors after definitive platinum based chemoradiotherapy for advanced stage HPV-negative head and neck cancer. (October 2022)

• Record Type: Journal Article
• Authors: de Roest, Reinout H.; van der Heijden, Martijn; Wesseling, Frederik W.R.; de Ruiter, Emma J.; Heymans, Martijn W.; Terhaard, Chris; Vergeer, Marije R.; Buter, Jan; Devriese, Lot A.; de Boer, Jan Paul; Navran, Arash; Hoeben, Ann; Vens, Conchita; van den Brekel, Michiel; Brakenhoff, Ruud H.; Leemans, C. René; Hoebers, Frank
• Is Part Of: Radiotherapy and oncology. Volume 175(2022)
• Page Start: 112
• Page End: 121
• Publication Date: 2022-10
• Subjects: HNSCC -- Chemoradiotherapy -- Cisplatin -- HPV-negative -- Advanced stage; ACE-27 Adult comorbidity evaluation – 27 -- CRT Chemoradiotherapy -- DHNOCG Dutch Head and Neck Oncology Cooperative Group -- DM Distant metastasis -- HNSCC Head and neck squamous cell carcinoma -- HPSCC Hypopharyngeal squamous cell carcinoma -- HPV Human papilloma virus -- IMRT Intensity-Modulated Radiation Therapy -- IQR Interquartile range -- KM Kaplan Meier -- LSCC Laryngeal squamous cell carcinoma -- LRR Locoregional recurrence -- MI Multiple imputation -- MV Multi variable -- OPSCC Oropharyngeal squamous cell carcinoma -- OS Overall survival -- OTT Overall treatment time -- SEQ Sequential boost -- SIB Simultaneous integrated boost -- SCC Squamous Cell Carcinoma -- SPT Second primary tumor; Oncology -- Periodicals; Radiotherapy -- Periodicals; Tumors -- Periodicals; Medical Oncology -- Periodicals; Neoplasms -- radiotherapy -- Periodicals; Radiotherapy -- Periodicals; Radiothérapie -- Périodiques; Cancérologie -- Périodiques; Tumeurs -- Périodiques; Electronic journals; 616.9940642
• DOI: 10.1016/j.radonc.2022.08.013
• Languages: English
• ISSNs: 0167-8140

Abstract

Highlights: Platinum-based CRT for HPV-neg HNSCC has unique treatment course and outcome pattern. CRT is often too toxic, in ∼35% of patients the cisplatin-dose plan needed changes. Switching to carboplatin when cisplatin is too toxic seems not beneficial for OS (HR 1.49 vs HR 1.59). Development of DM was strongly associated with boosting method (SEQ vs SIB; OR 1.91). Abstract: Background: Definitive concomitant cisplatin-based chemoradiotherapy (CRT) is the current gold standard for most patients with advanced stage head and neck squamous cell carcinoma (HNSCC) of the pharynx and larynx. Since previous meta-analysis on CRT outcomes in HNSCC have been reported, advances have been made in radiotherapy techniques and clinical management, while HPV-status has been identified as a strong confounding prognostic factor in oropharyngeal cancer. Here, we present real-world outcome data from a large multicenter cohort of HPV-negative advanced stage HNSCC treated with CRT using contemporary IMRT-based techniques. Method: Retrospective data were collected from a multicenter cohort of 513 patients treated with definitive concurrent platinum-based CRT with curative intent between January 2009 and August 2017. Only patients with HPV-negative advanced stage (III-IV) HNSCC were included. A prognostic model for outcome was developed based on clinical parameters and compared to TNM. Results: Nearly half of the 513 patients (49%) had an oropharyngeal tumor, often locally advanced (73.3% T3-T4b) and with involvement of the regional lymph nodes (84%). Most patients (84%) received cisplatin as single agent. In total 66% received the planned number of cycles and 75% reached a cumulative cisplatin dose of ≥200 mg/m 2 . Locoregional control was achieved in 324 (63%) patients during follow-up, and no association with tumor sites was observed (p = 0.48). Overall survival at 5 year follow-up was 47%, with a better survival for laryngeal cancer (p = 0.02) compared to other sites. A model with clinical variables (gender, high pre-treatment weight loss, N2c/N3-stage and <200 mg/m 2 dose of cisplatin) provided a noticeably stronger association with overall survival than TNM-staging (C- index 0.68 vs 0.55). Simultaneous Integrated Boosting (SIB) significantly outperformed Sequential Boosting (SEQ) to reduce the development of distant metastasis (SEQ vs SIB: OR 1.91 (1.11–3.26; p = 0.02). Conclusion: Despite advances in clinical management, more than a third of patients with HPV-negative HNSCC do not complete CRT treatment protocols due to cisplatin toxicity. A model that consists of clinical variables and treatment parameters including cisplatin dose provided the strongest association with overall survival. Since cisplatin toxicity is a major obstacle in completing definitive CRT, the development of alternative and less toxic radiosensitizers is therefore warranted to improve treatment results. The association of RT-boost technique with distant metastasis is an important finding and requires further study.